



PAN AMERICAN HEALTH ORGANIZATION
WORLD HEALTH ORGANIZATION



42nd DIRECTING COUNCIL

52nd SESSION OF THE REGIONAL COMMITTEE

Washington D.C., 25-29 September 2000

RESOLUTION

CD42.R8

VACCINES AND IMMUNIZATION

THE 42nd DIRECTING COUNCIL,

Having considered the report of the Director on vaccines and immunization (Document CD42/8) and taking note of the progress being made by all countries in the control of vaccine-preventable diseases;

Taking into account that there is still a considerable number of children who are not receiving the benefits of immunization;

Cognizant of the fact that major efforts are needed to achieve the goal of measles eradication by the end of the year 2000; and

Considering that the sustainability of immunization programs and control/eradication of vaccine-preventable diseases require a permanent effort by the health sector at all levels,

RESOLVES

1. To urge Member States to:

(a) maintain a high degree of priority in the financing of their national immunization programs, including the costs related to the introduction of new vaccines;

(b) target a 95% vaccination coverage for all antigens in every district of the country as the national goal;

(c) ensure that all measures necessary to interrupt the transmission of measles are put in place, including those related to mop-up operations and strengthening of surveillance and complete case investigation;

(d) initiate activities related to the containment of any laboratory material that may harbor specimens of wild poliovirus, to ensure that global certification of eradication is eventually accomplished;

(e) implement periodic multidisciplinary evaluations of their national immunization programs to identify any constraints that may hamper the equitable access to measures aimed at the control of vaccine-preventable diseases;

(f) ensure that all vaccines used in national immunization programs comply with national and international standards.

2. Request the Director to:

(a) collaborate with Member States in the containment of biological material that may harbor the wild poliovirus;

(b) support the networks of national control authorities and national control laboratories to ensure that vaccines of reliable quality are used in all countries;

(c) support the national program evaluations in coordination with other collaborating partners;

(d) assist the relevant Member States in benefiting maximally from the Global Alliance for Vaccines and Immunization.

(Final Report, CD42, 14-16)